Automated Synthesis of Large DNA Fragments

DNA 大片段的自动合成

• 批准号: 6702317
• 负责人: John Thomas Mulligan
• 金额: $ 80.02万
• 依托单位: BLUE HERON BIOTECHNOLOGY, INC.
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-08-01 至 2006-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6702317
• 关键词: artificial intelligence; biomedical automation; biomedical equipment development; biotechnology; computer program /software; computer system design /evaluation; genetic manipulation; molecular cloning; nucleic acid chemical synthesis; oligonucleotides; technology /technique development

DESCRIPTION (provided by applicant): The long-term objective of this research is to provide researchers with fast, inexpensive access to any DNA sequence. Gene-based research is at the heart of drug discovery today. The ability to acquire and modify genes is integral to much of the basic research supported by the NIH; research which will be the foundation of future therapeutic research. Fast and cost-effective gene synthesis has the potential to improve the speed and productivity of both applied and basic biomedical research and thus to improve healthcare very broadly. This application's specific objective is to build, test and refine an automated system capable of unattended production of 50,000 base pairs of synthetic DNA fragments in less than 18 hours. This system will first be commercialized by incorporating it into Blue Heron Biotechnology's existing automated gene synthesis process. In the future, it could be the basis for a commercial instrument for gene synthesis. The instrument will be based on the novel and innovative technologies for gene assembly developed in the Phase I portion of this research. It will involve both custom-designed instruments and the incorporation of available automation for plate handling and plate storage, novel attachment chemistry and custom-manufactured solid-phase supports.

描述(由申请人提供)：这项研究的长期目标是为研究人员提供快速、廉价的任何DNA序列访问。基于基因的研究是当今药物发现的核心。获取和修改基因的能力是美国国立卫生研究院支持的许多基础研究的组成部分；这些研究将成为未来治疗研究的基础。快速和经济高效的基因合成有可能提高应用和基础生物医学研究的速度和生产率，从而在非常广泛的范围内改善医疗保健。该应用程序的特定目标是建立、测试和改进一个自动化系统，该系统能够在不到18小时的时间内无人值守地生产50,000个碱基对的合成DNA片段。该系统将首先商业化，将其纳入蓝鹭生物技术公司现有的自动化基因合成过程。在未来，它可能成为基因合成商业仪器的基础。该仪器将基于在这项研究的第一阶段中开发的新颖和创新的基因组装技术。它将包括定制设计的仪器，以及将现有的板材处理和存储自动化、新颖的附着化学和定制的固相支撑物结合在一起。